Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition
European Journal of Clinical Investigation · 2024
DOI: 10.1111/eci.14272 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Alexander M Cao Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 87 Literaturangaben.
Abstract (Originalsprache)
Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as a novel class of drugs with cardioprotective effects through their lipid‐lowering effects.
Objective
This review aims to discuss existing and novel strategies of PCSK9 inhibition, providing an overview of established randomized controlled trials and ongoing outcome trials that assess the efficacy and long‐term safety of PCSK9 inhibitors. It also explores the evolving role of PCSK9 beyond lipid metabolism and outlines the pleiotropic actions of PCSK9 inhibition in various disorders and future directions including novel strategies to target PCSK9.
Conclusion
PCSK9 inhibition shows promise not only in lipid metabolism but also in other disease processes, including atherosclerotic plaque remodeling, acute coronary syndrome, stroke, inflammation, and immune response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Alexander M Cao Zhang
Zitieren
APA
Cao Zhang, A. M., Ziogos, E., Harb, T., Gerstenblith, G., & Leucker, T. M. (2024). Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14272
Vancouver
Cao Zhang AM, Ziogos E, Harb T, Gerstenblith G, Leucker TM. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14272
BibTeX
@article{CaoZhang2024,
author = {Cao Zhang, Alexander M and Ziogos, Efthymios and Harb, Tarek and Gerstenblith, Gary and Leucker, Thorsten M},
title = {Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition},
journal = {European Journal of Clinical Investigation},
year = {2024},
doi = {10.1111/eci.14272}
}
EUVIMED